pps


Pentosan Polysulphate Sodium (PPS) is a semi-synthetic drug manufactured from European beech xylans that are sulphated to produce a negatively charged product that mimics glycosaminoglycans (GAGs). These complex carbohydrates have a regulatory role in the body through interacting with proteins involved with inflammation. PPS also has a mild antithrombotic activity.


pps


Pentosan Polysulphate Sodium (PPS) is a semi-synthetic drug manufactured from European beech xylans that are sulphated to produce a negatively charged product that mimics glycosaminoglycans (GAGs). These complex carbohydrates have a regulatory role in the body through interacting with proteins involved with inflammation. PPS also has a mild antithrombotic activity (1/15th that of heparin).

Safety profile


To achieve European and FDA approval, PPS has been examined in toxicology and safety studies across several species of animals to humans for more than 50 years. It has been ingested orally, infused in the bladder, injected (IV, intramuscularly and subcutaneously) and administered intranasally in a recent Paradigm toxicology study. It has a robust safety profile for long term use in humans at 300mg daily dose ingested, and when injected at doses of 3mg/kg into inflamed tissue.


Interstitial cystitis


While interstitial cystitis has a complex pathology, PPS provided in tablet form or through bladder infusion is suggested to act through a coating effect on the bladder epithelium to replace a defective glycosaminoglycan layer, as well as through anti-inflammatory action by inhibition of mast cell degranulation. Elmiron for oral administration is approved in the US (FDA) and Australia (TGA) and marketed by Janssen Pharmaceuticals.


deep vein thrombosis


PPS in injectable form is well established in Europe for prevention of thromboembolism and acute blood vessel occlusions in humans. A key activity of PPS in this application is its anti-clotting activity.

PPS delivery for human use in an injectable form is not currently approved in Australia, so the above treatments are not available in Australia.


Repurposing PPS for new applications


Currently we focus on repurposing PPS for the treatment of bone marrow edema (BME), respiratory disease (Allergic Rhinitis), and alphaviral arthritis (Ross River Virus and Chikungunya), where a key feature of the activity of PPS is its anti-inflammatory and tissue regenerative properties. There are other disease applications involving inflammation that are of possible interest to Paradigm.